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It remains largely unclear how antigen-presenting cells encounter effector or memory T cells 41 
efficiently in the periphery. Here we used a murine contact hypersensitivity model and 42 
showed that upon epicutaneous antigen challenge, dendritic cells (DCs) formed clusters with 43 
effector T cells in dermal perivascular areas to promote in situ proliferation and activation of 44 
skin T cells in an antigen- and integrin LFA-1-dependent manner. We found that DCs 45 
accumulated in perivascular areas and DC clustering was abrogated by macrophage-depletion. 46 
Interleukin 1α (IL-1α) treatment induced the production of the chemokine CXCL2 from 47 
dermal macrophages, and DC clustering was suppressed by blockade of either IL-1 receptor 48 
(IL-1R) or CXCR2, the receptor for CXCL2. These findings suggest that dermal leukocyte 49 
cluster is an essential structure for elicitation of the acquired cutaneous immunity. 50 
  51 
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Boundary tissues, including the skin, are continually exposed to foreign antigens, which must 52 
be monitored and possibly eliminated. Upon foreign antigen exposure, skin dendritic cells 53 
(DCs), including epidermal Langerhans cells (LCs), capture the antigens and migrate to 54 
draining lymph nodes (LNs) where antigen presentation to naïve T cells occurs mainly in the 55 
T cell zone. In this location naïve T cells accumulation in the vicinity of DCs is mediated by 56 
CCR7 signaling1. The T cell zone in the draining LNs facilitates the efficient encounter of 57 
antigen-bearing DCs with antigen-specific naïve T cells. 58 
As opposed to LNs, the majority of skin T cells, including infiltrating skin T cells and skin 59 
resident T cells, have an effector-memory phenotype2. In addition, antigen presentation to 60 
skin T cells by antigen-presenting cells (APCs) is the crucial step in elicitation of acquired 61 
skin immune responses, such as contact dermatitis. Therefore, we hypothesize that 62 
antigen-presentation in the skin should be substantially different from that in LNs. ,Previous 63 
studies using murine contact hypersensitivity (CHS), as a model of human contact dermatitis, 64 
have revealed that dermal DCs (dDCs), but not epidermal LCs, have a pivotal role in the 65 
transport and presentation of antigen to the LNs3. In the skin, however, it remains unclear 66 
which subset of APCs presents antigens to skin T cells, and how skin T cells efficiently 67 
encounter APCs. In addition, dermal macrophages are key modulators in CHS response4, but 68 
the precise mechanisms by which macrophages are involved in antigen recognition in the 69 
skin have not yet been clarified. These unsolved questions prompted us to focus where skin T 70 
cells recognize antigens and how skin T cells are activated in the elicitation phase of acquired 71 
cutaneous immune responses, such as CHS.  72 
When keratinocytes encounter foreign antigens, they immediately produce various 73 
pro-inflammatory mediators such as interleukin 1(IL-1) and tumor necrosis factor (TNF) in 74 
an antigen-nonspecific manner5, 6. IL-1 family proteins are considered important modulators 75 
in CHS responses, because hapten-specific T cell activation was shown to be impaired in 76 
IL-1α and IL-1β-deficient mice, but not in TNF-deficient mice7. IL-1α and IL-1β are 77 
agonistic ligands of the IL-1 receptor (IL-1R). While IL-1α is stored in keratinocytes and 78 
secreted upon exposure to nonspecific stimuli, IL-1β is produced mainly by epidermal LCs 79 
and dermal mast cells in an inflammasome-dependent manner via NALP3 and caspase 1/11 80 
activation. Because these pro-inflammatory mediators are crucial in the initiation of acquired 81 
immune responses such as CHS, it is of great interest to understand how IL-1 modulates 82 
antigen recognition by skin T cells. 83 
  Using a murine CHS model, here we examined how DCs and effector T cells encounter 84 
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each other efficiently in the skin. We found that upon encounter with antigenic stimuli dDCs 85 
formed clusters in which effector T cells were activated and proliferated in an 86 
antigen-dependent manner. These DC–T cell clusters were initiated by skin macrophages via 87 
IL-1R signaling and were essential for the establishment of cutaneous acquired immune 88 
responses. 89 
 90 
 91 
RESULTS 92 
DC–T cell clusters are formed at antigen-challenged sites 93 
To explore immune cell accumulation in the skin, we examined the clinical and histological 94 
features of elicitation of human allergic contact dermatitis. Allergic contact dermatitis is the 95 
most common of eczematous skin diseases, affecting 15–20% of the general population 96 
worldwide8, and is mediated by T cells. Although antigens may be applied relatively evenly 97 
over the surface of skin, clinical manifestations commonly include discretely distributed 98 
small vesicles (Fig. 1a), suggesting an uneven occurrence of intense inflammation. 99 
Histological examination of allergic contact dermatitis showed spongiosis, intercellular 100 
edema in the epidermis and co-localization of perivascular infiltrates of CD3+ T cells and 101 
spotty accumulation of CD11c+ DCs in the dermis, especially beneath the vesicles (Fig. 1b). 102 
These findings led us to hypothesize that focal accumulation of T cells and DCs in the dermis 103 
may contribute to vesicle formation in early eczema. 104 
To characterize the DC–T cell clusters in elicitation reactions, we obtained time-lapse 105 
images in a murine model of CHS using two-photon microscopy. T cells were isolated from 106 
the draining LNs of 2, 4-dinitrofluorobenzene (DNFB)-sensitized mice, labeled and 107 
transferred into CD11c-yellow fluorescent protein (YFP) mice. In the steady state, YFP+ 108 
dDCs distributed diffusely (Fig. 1c), representing nondirected movement in a random fashion, 109 
as reported previously (Supplementary Fig. 1). After topical challenge with DNFB, YFP+ 110 
dDCs transiently increased their velocities and formed clusters in the dermis, with the clusters 111 
becoming larger and more evident after 24 h (Fig. 1c and Supplementary Movie 1). At the 112 
same time, transferred T cells accumulated in the DC clusters and interacted with YFP+ DCs 113 
for several hours (Fig. 1d and Supplementary Movie 2). Thus, the accumulation of DCs and 114 
T cells in the dermis is observed in mice during CHS responses. We observed that the 115 
intercellular spaces between keratinocytes overlying the DC–T cell clusters in the dermis 116 
were enlarged (Fig. 1e), replicating observations in human allergic contact dermatitis (Fig. 117 
1b).  118 
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We next sought to determine which of the two major DC populations in skin, epidermal LCs 119 
or dDCs, were essential for the elicitation of CHS. To deplete all cutaneous DC subsets, 120 
Langerin-diphtheria toxin receptor (DTR) mice were transferred with bone marrow (BM) 121 
cells from CD11c-DTR mice. To selectively deplete LCs or dDCs, Langerin-DTR or 122 
C57BL/6 mice were transferred with BM cells from C57BL/6 mice or CD11c-DTR mice, 123 
respectively (Supplementary Fig. 2a, b). We injected diphtheria toxin (DT) for depletion of 124 
each DC subset before elicitation and found that ear swelling and inflammatory histological 125 
findings were significantly attenuated in the absence of dDCs, but not in the absence of LCs 126 
(Fig. 1f and Supplementary Fig. 2c). In addition, interferon (IFN)-γ production in skin T 127 
cells was strongly suppressed in dDC-depleted mice (Fig. 1g). These results suggest that 128 
dDCs, and not epidermal LCs, are essential for T cell activation and the elicitation of CHS 129 
responses. 130 
 131 
Skin effector T cells proliferate in situ in an antigen-dependent manner 132 
To evaluate the impact of DC–T cell clusters in the dermis, we determined whether T cells 133 
had acquired the ability to proliferate via DC–T cell accumulation in the dermis. CD4+ or 134 
CD8+ T cells purified from the draining LNs of DNFB-sensitized mice were labeled with 135 
CellTraceTM Violet and transferred into naïve mice. Twenty-four hours after DNFB 136 
application, we collected the skin to evaluate T cell proliferation by dilution of fluorescent 137 
intensity. The majority of infiltrating T cells were CD44+ CD62L- effector T cells 138 
(Supplementary Fig. 2d). Among the infiltrating T cells, CD8+ T cells proliferated actively, 139 
whereas the CD4+ T cells showed low proliferative potency (Fig. 2a). This T cell 140 
proliferation was antigen-dependent, because 2,4,6-trinitrochlorobenzene (TNCB)-sensitized 141 
T cells exhibited low proliferative activities in response to DNFB application (Fig. 2a). In 142 
line with this finding, the DC–T cell conjugation time was prolonged in the presence of 143 
cognate antigens (Fig. 2b), and the T cells interacting with DCs within DC–T cell clusters 144 
proliferated (Fig. 2c and Supplementary Movie 3). Our findings indicate that skin effector T 145 
cells conjugate with DCs and proliferate in situ in an antigen-dependent manner. 146 
 147 
CD8+ T cell activation in DC–T cell clusters is LFA-1 dependent 148 
A sustained interaction between DCs and naïve T cells, which is known as an immunological 149 
synapse, is maintained by cell adhesion molecules9. Particularly, the integrin LFA-1 on T 150 
cells binds to cell surface glycoproteins, such as intercellular adhesion molecule-1 (ICAM-1), 151 
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on APCs, which is essential for naïve T cell proliferation and activation during antigen 152 
recognition in the LNs. To examine whether LFA-1-ICAM-1 interactions are required for 153 
effector T cell activation in DC–T cell clusters in the skin, an anti-LFA-1 neutralizing 154 
antibody, KBA, was intravenously injected 14 h after elicitation with DNFB in CHS. KBA 155 
administration reduced T cells accumulation in the dermis (Fig. 3a). The velocity of T cells in 156 
the cluster was 0.65 ± 0.29 µm/min 14 h after DNFB challenge and increased up to 3-fold 157 
(1.64± 1.54 µm/min) at 8 h after treatment with KBA, while it was not affected by treatment 158 
with an isotype-matched control IgG (Fig. 3b). At the outside of clusters, T cells smoothly 159 
migrated at the mean velocity of 2.95 ± 1.19 µm/min, consistent with previous results10, and 160 
was not affected by control-IgG treatment (data not shown). Treatment with KBA also 161 
attenuated ear swelling significantly (Fig. 3c), as well as IFN-γ production by skin CD8+ T 162 
cells (Fig. 3d, e). These results suggest that DC–effector T cell conjugates are 163 
integrin-dependent, similar to the DC–naïve T cell interactions in draining LNs. 164 
 165 
Skin macrophages are required for dDC clustering 166 
We next examined the initiation factors of DC–T cell accumulation. dDC clusters were also 167 
formed in response to the initial application of hapten (sensitization phase), but their number 168 
was significantly decreased 48 h after sensitization, while DC clusters persisted for 48 h in 169 
the elicitation phase (Fig. 4a and Supplementary Fig. 3a). These DC clusters were 170 
abrogated 7 days after DNFB application (data not shown). These observations suggest that 171 
DC–T cell accumulation is initiated by DC clustering, which then induces the accumulation, 172 
proliferation and activation of T cells, a process that depends on the presence of 173 
antigen-specific effector T cells in situ. DC clusters were also induced by solvents such as 174 
acetone or adjuvants such as dibutylphthalic acid and Mycobacterium bovis BCG-inoculation 175 
(Supplementary Fig. 3b, c). In addition, DC clusters were observed not only in the ear skin, 176 
but also in other regions such as the back skin and the footpad (Supplementary Fig. 3d). 177 
These results suggest that DC cluster formation is not an ear-specific event, but a general 178 
mechanism during skin inflammation. 179 
The initial DC clusters were not decreased in recombination activating gene 2 180 
(RAG2)-deficient mice, in which T and B cells are absent, in lymphoid tissue inducer 181 
cell-deficient aly/aly mice 11 or in mast cell or basophil-depleted mice, using MasTRECK or 182 
BasTRECK mice12, 13 (Fig. 4b). In contrast, DC clusters were abrogated in C57BL/6 mice 183 
transferred with BM from LysM-DTR mice, in which both macrophages and neutrophils 184 
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were depleted by treatment with DT (Fig. 4b, c). The depletion of neutrophils alone, by 185 
administration of anti-Ly6G antibody (1A8), did not interfere with DC cluster formation (Fig. 186 
4b), which suggested that macrophages, but not neutrophils, were required during the 187 
formation of DC clusters. Of note, DC cluster formation was not attenuated by anti-LFA-1 188 
neutralizing KBA antibody treatment (Supplementary Fig. 3e, f), suggesting that 189 
macrophages-DCs interaction were LFA-1-independent. Consistent with the DC cluster 190 
formation, the elicitation of the CHS response (Fig. 4d) and IFN-γ production by skin T cells 191 
(Fig. 4e) were significantly suppressed in LysM-DTR BM chimeric mice treated with DT. 192 
Thus, skin macrophages were required for formation of DC clusters, which was necessary for 193 
T cell activation and the elicitation of CHS. 194 
 195 
Macrophages are required for perivascular DCs clustering 196 
To examine the kinetics of dermal macrophage and DCs in vivo, we visualized them by 197 
two-photon microscopy. In vivo labeling of blood vessels with tetramethylrhodamine 198 
isothiocyanate (TRITC)-conjugated dextran revealed that dDCs distributed diffusely in the 199 
steady state (Fig. 5a, left). After hapten-application to the ear of previously sensitized mice, 200 
dDCs accumulated mainly around post-capillary venules (Fig. 5a, right and Fig. 5b). 201 
Time-lapse imaging revealed that some of dDCs showed directional migration toward 202 
TRITC-positive cells that were labeled red by incorporating extravasated TRITC-dextran 203 
(Fig. 5c and Supplementary Movie 4). The majority of TRITC-positive cells were F4/80+ 204 
CD11b+ macrophages (Supplementary Fig. 4a). These observations prompted us to examine 205 
the role of macrophages in DC accumulation. We used a chemotaxis assay to determine 206 
whether macrophages attracted the DCs. dDCs and dermal macrophages were isolated from 207 
dermal skin cell suspensions and incubated in a transwell assay for 12 h. dDCs placed in the 208 
upper wells efficiently migrated to the lower wells that contain dermal macrophages (Fig. 5d). 209 
But this dDC migration was not observed when macrophages were absent in the lower wells 210 
(Fig. 5d). Thus, dermal macrophages have a capacity to attract dDCs in vitro, which may 211 
lead to dDC accumulation around post-capillary venules. 212 
 213 
IL-1α is required for DC cluster formation upon antigen challenge 214 
We attempted to explore the underlying mechanism of DC cluster formation. We observed 215 
that DC accumulation occurred during the first application of hapten (Fig. 4a), which 216 
suggested that an antigen-nonspecific mechanism, such as production of the 217 
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pro-inflammatory mediator IL-1, may initiate DC clustering. Hapten-induced DC 218 
accumulation was not decreased in NALP3- or caspase-1-11-deficient mice, but was 219 
decreased significantly in IL-1R1-deficient mice, which lack a receptor for IL-1α, IL-1β, and 220 
IL-1R antagonist, or after the subcutaneous administration of an IL-1R antagonist (Fig. 6a,b). 221 
Consistent with these observations, the elicitation of CHS and IFN-γ production by skin T 222 
cells were significantly attenuated in mice that lack both IL-1α and IL-1β (Fig. 6c, d). In 223 
addition, the formation of dDC clusters was suppressed significantly by the subcutaneous 224 
injection of an anti-IL-1α neutralizing antibody, but only marginally by an anti-IL-1β 225 
neutralizing antibody (Fig. 6b). Because keratinocytes are known to produce IL-1α upon 226 
hapten application 14, our results suggest that IL-1α has a major role in mediating the 227 
formation of DC clustering. 228 
 229 
M2 macrophages produce CXCL2 to attract dDCs 230 
To further characterize how macrophages attract dDCs, we examined Il1r1 expression in 231 
BM-derived M1 and M2 macrophages, classified as such based on the differential mRNA 232 
expression of Tnf, Nos2, Il12a, Arg1, Retnla and Chi313 (Supplementary Fig. 4b) 15. We 233 
found that M2 macrophages had higher expression of Il1r1 mRNA compared to M1 234 
macrophages (Fig. 6e). We also found that the subcutaneous injection of pertussis toxin, a 235 
inhibitory regulative G protein (Gi)-specific inhibitor, almost completely abrogated DC 236 
cluster formation in response to hapten-stimuli (Fig. 6b) suggesting that signaling through 237 
Gi-coupled chemokines was required for DC cluster formation.  238 
  We next used microarrays to examine the effect of IL-1α on the expression of chemokines 239 
in M1 and M2 macrophages. IL-1α treatment did not enhance chemokine expression in M1 240 
macrophages, whereas it increased Ccl5, Ccl17, Ccl22 and Cxcl2 mRNA expression in M2 241 
macrophages (Supplementary Table 1). Among them, Cxcl2 expression was enhanced most 242 
prominently by treatment with IL-1α, a result validated by real-time polymerase chain 243 
reaction (PCR) analysis (Fig. 6f). Consistently, Cxcl2 mRNA expression was significantly 244 
increased in DNFB-painted skin (Supplementary Fig. 5a) and was not affected by 245 
neutrophil depletion with 1A8 (Supplementary Fig. 5b, c). In addition, IL-1α-treated dermal 246 
macrophages produced Cxcl2 mRNA in vitro (Supplementary Fig. 5d). These results 247 
suggest that dermal macrophages, but not neutrophils, are the major source of CXCL2 during 248 
CHS. We also detected high expression of the mRNA for Cxcr2, the receptor for CXCL2, in 249 
DCs (Supplementary Fig. 5e), which prompted us to examine the role of CXCR2 on dDCs. 250 
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The formation of DC clusters in response to hapten stimuli was substantially reduced by the 251 
intraperitoneal administration of the CXCR2 inhibitor SB265610 16 (Fig. 6g). In addition, 252 
SB265610-treatment during the elicitation of CHS inhibited ear swelling (Fig. 6h) and IFN-γ 253 
production by skin T cells (Fig. 6i). 254 
Taken together, in the absence of effector T cells specific for a cognate antigen (i.e. in the 255 
sensitization phase of CHS), DC clustering is a transient event, and hapten-carrying DCs 256 
migrate into draining LNs to establish sensitization. On the other hand, in the presence of the 257 
antigen and antigen-specific effector or memory T cells, DC clustering is followed by T cell 258 
accumulation (i.e. in the elicitation phase of CHS) (Supplementary Fig. 6). Thus, dermal 259 
macrophages are essential for initiating DC cluster formation through the production of 260 
CXCL2, and that DC clustering plays an important role for efficient activation of skin T cells. 261 
 262 
 263 
DISCUSSION 264 
Although the mechanistic events in the sensitization phase in cutaneous immunity have been 265 
studied thoroughly over 20 years17, 18, what types of immunological events occur during the 266 
elicitation phases in the skin has remained unclear. Here we describe the antigen-dependent 267 
induction of DC and T cell clusters in the skin in a murine model of CHS and show that 268 
effector T cells-DCs interactions in these clusters are required to induce efficient 269 
antigen-specific immune responses in the skin. We show that dDCs, but not epidermal LCs, 270 
are essential for antigen presentation to skin effector T cells and they exhibit sustained 271 
association with effector T cells in an antigen- and LFA-1-dependent manner. IL-1α, and not 272 
the inflammasome, initiates the formation of these perivascular DC clusters. 273 
  Epidermal contact with antigens triggers release of IL-1 in the skin14. Previous studies have 274 
shown that the epidermal keratinocytes constitute a major reservoir of IL-1α6 and mechanical 275 
stress to keratinocytes permits release of large amounts of IL-1α even in the absence of cell 276 
death19. The cellular source of IL-1α in this process remains unclear. We show that IL-1α 277 
activates macrophages that subsequently attract dDCs, mainly to areas around post-capillary 278 
venules, where effector T cells are known to transmigrate from the blood into the skin20. In 279 
the presence of the antigen and antigen-specific effector T cells, DC clustering is followed by 280 
T cell accumulation. Therefore, we propose that these perivascular dDC clusters may provide 281 
antigen-presentation sites for efficient effector T cell activation. This is suggested by the 282 
observations that CHS responses and intracutaneous T cell activation were attenuated 283 
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significantly in the absence of these clusters, in condition of macrophage depletion or 284 
inhibiting integrin functions, IL-1R signaling21, 22 or CXCR2 signaling23. 285 
  In contrast to the skin, antigen presentations in other peripheral barrier tissues is relatively 286 
well understood. In submucosal areas, specific sentinel lymphoid structures called 287 
mucosa-associated lymphoid tissue (MALT), serve as peripheral antigen presentation sites24, 288 
and lymphoid follicles are present in the normal bronchi (bronchus-associated lymphoid 289 
tissue; BALT). These structures serve as antigen presentation sites in non-lymphoid 290 
peripheral organs. By analogy, the concept of skin-associated lymphoid tissue (SALT) was 291 
proposed in the early 1980’s, based on findings that cells in the skin are capable of capturing, 292 
processing and presenting antigens25, 26. However, the role of cellular skin components as 293 
antigen presentation sites has remained uncertain. Here we have identified an inducible 294 
structure formed by dermal macrophages, dDCs and effector T cells, which seem to 295 
accumulate sequentially. Because formation of this structure is essential for efficient effector 296 
T cell activation, these inducible leukocyte clusters may function as SALTs. Unlike MALTs, 297 
these leukocyte clusters are not found at steady state, but are induced during the development 298 
of an adaptive immune response. Therefore, these clusters may be better named as inducible 299 
SALTs (iSALT), similar to inducible BALTs (iBALT) in the lung27. In contrast to iBALTs, we 300 
could not identify naïve T cells or B cells in SALTs (data not shown), suggesting that the 301 
leukocyte clusters in the skin may be specialized for effector T cell activation but not for 302 
naïve T cell activation. Our findings suggest that approaches to the selective inhibition of this 303 
structure may have novel therapeutic benefit in inflammatory disorders of the skin. 304 
 305 
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METHODS 471 
Mice 472 
Female 8- to 12-week-old C57BL/6-background mice were used in this study. C57BL/6N 473 
mice were purchased from SLC (Shizuoka, Japan). Langerin-eGFP-DTR28, CD11c-DTR29, 474 
CD11c-YFP30, LysM-DTR31, Rag2-deficient32, MasTRECK12, 13, BasTRECK 12, 13, 475 
ALY/NscJcl-aly/aly11, IL-1α/β-deficient33, IL-1R1-deficient34, NLRP3-deficient35, and 476 
caspase-1/11-deficient mice36 were described previously. All experimental procedures were 477 
approved by the Institutional Animal Care and Use Committee of Kyoto University Graduate 478 
School of Medicine. 479 
 480 
Human Subjects 481 
Human skin biopsy samples were obtained from a nickel-reactive patch after 48 h from 482 
placement of nickel patch tests in patients with a previously proven allergic contact dermatitis. 483 
A biopsy of petrolatum-occluded skin was also obtained as a control. Informed consent was 484 
obtained under IRB approved protocols at the Icahn School of Medicine at Mount Sinai 485 
School Medical Center, and the Rockefeller University in New York. 486 
 487 
Induction of contact hypersensitivity (CHS) response 488 
Mice were sensitized on shaved abdominal skin with 25 μl 0.5% (w/v) 489 
1-fluoro-2,4-dinitrofluorobenzene (DNFB; Nacalai Tesque, Kyoto, Japan) dissolved in 490 
acetone/olive oil (4/1). Five days later, the ears were challenged with 20 µl 0.3% DNFB. For 491 
adoptive transfer, T cells were magnetically sorted using auto MACS (Miltenyi Biotec, 492 
Bergisch Gladbach, Germany) from the draining LNs of sensitized mice and then transferred 493 
1x 107 cells intravenously into naïve mice. 494 
 495 
Depletion of cutaneous DC subsets, macrophages, and neutrophils 496 
To deplete all cutaneous DC subsets (including LCs), 6-week-old Langerin-DTR mice were 497 
irradiated (two doses of 550 Rad given 3 h apart) and were transferred with 1 x 107 BM cells 498 
from CD11c-DTR mice. Eight weeks later, 2 µg diphtheria toxin (DT; Sigma-Aldrich, St. 499 
Louis, MO) was intraperitoneally injected. To selectively deplete LCs, irradiated 500 
Langerin-DTR mice were transferred with BM cells from C57BL/6 mice, and 1 µg DT was 501 
injected. To selectively deplete dermal DCs, irradiated C57BL/6 mice were transferred with 502 
BM cells from CD11c-DTR mice, and 2 µg DT was injected. For macrophage depletion, 503 
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irradiated C57BL/6 mice were transferred with BM cells from LysM-DTR mice and 800 ng 504 
DT was injected. For neutrophil depletion, 0.5 mg/body anti-Ly6G antibody (1A8, BioXCell, 505 
Shiga, Japan) were intravenously administered to mice 24 h before experiment. 506 
 507 
Time-lapse imaging of cutaneous DCs, macrophages, and T cells 508 
Cutaneous DCs were observed using CD11c-YFP mice. To label cutaneous macrophages in 509 
vivo, 5 mg TRITC-dextran (Sigma-Aldrich) was intravenously injected and mice were left for 510 
24 h. At that time, cutaneous macrophages become fluorescent because they incorporated 511 
extravasated dextran. To label skin-infiltrating T cells, T cells from DNFB-sensitized mice 512 
were labeled with CellTracker Orange CMTMR (Invitrogen, Carlsbad, CA) and adoptively 513 
transferred. Keratinocytes and sebaceous glands were visualized with the subcutaneous 514 
injection of isolectin B4 (Invitrogen) and BODIPY (Molecular Probes, Carlsbad, CA), 515 
respectively. Mice were positioned on the heating plate on the stage of a two-photon 516 
microscope IX-81 (Olympus, Tokyo, Japan) and their ear lobes were fixed beneath a cover 517 
slip with a single drop of immersion oil. Stacks of 10 images, spaced 3 µm apart, were 518 
acquired at 1 to 7 min intervals for up to 24 h. To calculate T cell and DC velocities, movies 519 
from 3 independent mice were processed and analyzed using Imaris7.2.1 (Bitplane, South 520 
Windsor, CT) for each experiment. 521 
 522 
Histology and immunohistochemistry 523 
For histological examination, tissues were fixed with 10% formalin in phosphate buffer saline, 524 
and then embedded in paraffin. Sections with a thickness of 5 µm were prepared and 525 
subjected to staining with hematoxylin and eosin. For whole-mount staining, the ears were 526 
split into dorsal and ventral halves, and incubated with 0.5 M ammonium thiocyanate for 30 527 
min at 37°C 37. Then the dermal sheets were separated and fixed in acetone for 10 min at 528 
-20°C. After treatment with Image-iT FX Signal Enhancer (Invitrogen), the sheets were 529 
incubated with anti-mouse MHC class II antibody (eBioscience, San Diego, CA) followed by 530 
incubation with secondary antibody conjugated to Alexa 488 or 594 (Invitrogen). The slides 531 
were mounted using a ProLong Antifade kit with DAPI (Molecular Probes) and observed 532 
under a fluorescent microscope (BZ-900, KEYENCE, Osaka, Japan). The number/size of DC 533 
clusters were evaluated in 10 fields of 1mm2/ ear and were scored according to the criteria 534 
shown in Supplementary Fig. 5a. 535 
 536 
Natsuaki et al                                                                 20 
 
 537 
Cell isolation and flow cytometry 538 
To isolate skin lymphocytes, the ear splits were put into digestion buffer 539 
(RPMI supplemented with 2% fetal calf serum, 0.33 mg/ml of Liberase TL (Roche, Lewes, 540 
UK), and 0.05% DNase I (Sigma-Aldrich)) for 1 hr at 37°C. After the incubation, the tissue 541 
was disrupted by passage through a 70 µm cell strainer and stained with respective antibodies. 542 
For analysis of intracellular cytokine production, cell suspensions were obtained in the 543 
presence of 10 µg/ml of Brefeldine A (Sigma-Aldrich) and were fixed with Cytofix buffer, 544 
permeabilized with Perm/Wash buffer (BD Biosciences) as per the manufacturer’s protocol. 545 
To stain cells, anti-mouse CD4, CD8, CD11b, CD11c, B220, MHC class II, F4/80, IFN-γ, 546 
Gr1 antibodies and 7-amino-actinomycin D (7AAD) were purchased from eBioscience. 547 
Anti-mouse CD45 antibody (BioLegend, San Diego, CA), anti-TCR-β antibody (BioLegend), 548 
and anti-CD16/CD32 antibody (BD Biosciences) were purchased. Flow cytometry was 549 
performed using LSRFortessa (BD Biosciences) and analyzed with FlowJo (TreeStar, San 550 
Carlos, CA). 551 
 552 
Chemotaxis assay 553 
Chemotaxis was performed as described previously with some modifications 37. In brief, the 554 
dermis of the ear skin was minced and digested with 2 mg/ml collagenase type II 555 
(Worthington Biochemical, NY) containing 1 mg/ml hyaluronidase (Sigma-Aldrich) and 100 556 
µg/ml DNase I (Sigma-Aldrich) for 30 min at 37°C. DDCs and macrophages were isolated 557 
using auto-MACS. Alternatively, BM-derived DCs and macrophages were prepared. 1 x 106 558 
DCs were added to the 5 µm pore-size transwell insert (Corning, Cambridge, MA) and 5 x 559 
105 macrophages were added into the lower wells, and the cells were incubated at 37°C for 560 
12 h. A known number of fluorescent reference beads (FlowCount fluorospheres, Beckman 561 
Coulter, Fullerton, CA) were added to each sample to allow accurate quantification of 562 
migrated cells in the lower wells by flow cytometry. 563 
 564 
Cell proliferation assay with CellTraceTM Violet 565 
Mice were sensitized with 25 µl 0.5% DNFB or 7% trinitrochlorobenzene (Chemical Industry, 566 
Tokyo, Japan). Five days later, T cells were magnetically separated from the draining LNs of 567 
each group, and labeled with CellTraceTM Violet (Invitrogen) as per the manufacturer’s 568 
protocol. Ten million T cells were adoptively transferred to naïve mice, and the ears were 569 
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challenged with 20 µl of 0.5% DNFB. Twenty-four hours later, ears were collected and 570 
analyzed by flow cytometry. 571 
 572 
In vitro differentiation of DCs, M1 and M2-phenotype macrophages from BM cells 573 
BM cells from the tibias and fibulas were plated 5x106 cells/ 10cm dishes on day 0. For DC 574 
differentiation, cells were cultured at 37°C in 5% CO2 in cRPMI medium 575 
(RPMI supplemented with 1% L-glutamine, 1% Hepes, 0.1% 2ME and 10% fetal bovine 576 
serum) containing 10 ng/mL GM-CSF (Peprotech, Rocky Hill, NJ). For macrophages 577 
differentiation, BM cells were cultured in cRPMI containing 10 ng/mL M-CSF (Peprotech). 578 
Medium was replaced on days 3 and 6 and cells were harvested on day 9. To induce M1 or 579 
M2 phenotypes, cells were stimulated for 48 h with IFN-γ (10 ng/mL; R&D Systems, 580 
Minneapolis, MN) or with IL-4 (20 ng/mL; R&D Systems), respectively. 581 
 582 
In vitro IL-1α stimulation assay of dermal macrophages 583 
Dermal macrophages were separated from IL-1α/β-deficient mice33 to avoid pre-activation 584 
during cell preparations. Ear splits were treated with 0.25% trypsin/EDTA for 30 min at 37°C 585 
to remove epidermis and then minced and incubated with collagenase as previously described. 586 
CD11b+ cells were separated using MACS and 2x105 cells/well were incubated with or 587 
without 10 ng/ml IL-1α (R&D systems) in 96-well plate for 24 h. 588 
 589 
Blocking assay 590 
For LFA-1 blocking assay, mice were intravenously injected with 100 µg anti-LFA-1 591 
neutralizing antibody, KBA, 12-14 h after challenge with 20 µl 0.5% DNFB. For IL-1R 592 
blocking, mice were subcutaneously injected with 10 µg IL-1R antagonist (PROSPEC, East 593 
Brunswick, NJ) 5 h before challenge. For blocking of CXCR2, mice were intraperitoneally 594 
treated with 50 µg CXCR2 inhibitor SB26561016 (Tocris Bioscience, Bristol, UK) 6 h before 595 
and at hapten painting. 596 
 597 
Quantitative PCR analysis 598 
Total RNA was isolated using an RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was 599 
synthesized using a PrimeScript RT reagent kit (TaKaRa, Ohtsu, Japan) with random 600 
hexamers as per the manufacturer’s protocol. Quantitative PCR was carried out with a 601 
LightCycler 480 using a LightCycler SYBR Green I master (Roche) as per the 602 
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manufacturer’s protocol. The relative expression of each gene was normalized against that of 603 
Gapdh. Primer sequences are shown in Supplementary Table 2. 604 
 605 
Microarray analysis 606 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) as per the manufacturers’ 607 
protocol. An amplified sense-strand DNA product was synthesized by the Ambion WT 608 
Expression Kit (Life Technologies, Gaithersburg, MD), and was fragmented and labeled by 609 
the WT Terminal Labeling and Controls Kit (Affymetrix, Santa Clara, CA), and was 610 
hybridized to the Mouse Gene 1.0 ST Array (Affymetrix). We used the robust multi-array 611 
average algorithm for log transformation (log2) and normalization of the GeneChip data. 612 
Microarray data have been deposited in NCBI-GEO under accession number GSE53680. 613 
 614 
General experimental design and statistical analysis 615 
For animal experiments, a sample size of three to five mice per group was determined on the 616 
basis of past experience in generating statistical significance. Mice were randomly assigned 617 
to study groups and no specific randomization or blinding protocol was used. Sample or 618 
mouse identity was not masked for any of these studies. Statistical analyses were performed 619 
using Prism software (GraphPad Software Inc.). Normal distribution was assumed a priori for 620 
all samples. Unless indicated otherwise, an unpaired parametric t-test was used for 621 
comparison of data sets. In cases in which the data point distribution was not Gaussian, a 622 
nonparametric t-test was also applied. P values of less than 0.05 were considered significant. 623 
 624 
 625 
  626 
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Figure Legends 627 
Figure 1: DC–T cell cluster formation is responsible for epidermal eczematous conditions. 628 
(a) Clinical manifestations of allergic contact dermatitis in human skin 48 h after a patch test 629 
with nickel. Scale bar = 200 µm. (b) Hematoxylin and eosin, anti-CD3, and anti-CD11c 630 
staining of the human skin biopsy sample from an eczematous legion. Asterisks and 631 
arrowheads denote epidermal vesicles and dDC–T cell clusters, respectively. Scale bar = 250 632 
µm. (c) Sequential images of leukocyte clusters in the elicitation phase of CHS. White circles 633 
represent DC (green) and T cell (red) dermal accumulations. Scale bar = 100 µm. (d) A high 634 
magnification view of DC–T cell cluster in Fig.1c. Scale bar = 10 µm. (e) Intercellular edema 635 
of the epidermis overlying DC–T cell cluster in the dermis. Keratinocytes (red) are visualized 636 
with isolectin B4. The right panel shows the mean distance between adjacent keratinocytes 637 
above (+) or not above (-) DC–T cell cluster (n=20, each). Scale bar = 10 µm. (f) Ear 638 
swelling 24 h after CHS in subset-specific DC-depletion models (n = 5, each). *, P < 0.001. 639 
(g) The number (left) and the % frequency (right) of IFN-γ producing T cells in the ear 18 h 640 
after CHS with or without dDC-depletion (n = 5, each). *, P < 0.05. 641 
 642 
Figure 2: Antigen-dependent T cell proliferation in DC–T cell clusters. (a) T cell 643 
proliferation in the skin. CD4+ and CD8+ T cells from DNFB- (red) or TNCB- (blue) 644 
sensitized mice were labeled with CellTraceTM Violet and transferred. The dilutions of tracer 645 
in the challenged sites were examined 24 h later. (b) Conjugation time of DNFB- (red, n = 646 
160) or TNCB-sensitized (blue, n = 60) T cells with dDCs 24 h after DNFB challenge. *, P < 647 
0.05. (c) Sequential images of dividing T cells (red) in DC–T cell clusters. Green represents 648 
dDCs. Arrowheads represent a dividing T cell. 649 
 650 
Figure 3: LFA-1 is essential for the persistence of DC–T cell clustering and for T cell 651 
activation in the skin. (a) DC (green) and T cell (red) clusters in the DNFB-challenged site 652 
before (0 h) and 9 h after KBA or isotype-matched IgG treatment. Scale bar = 100 µm. (b) 653 
Fold changes of T cell velocities in DNFB-challenged sites after KBA or control IgG 654 
treatment (n = 30, each). (c) Ear swelling 24 h after KBA (red) or control IgG (black) 655 
treatment with DNFB challenge (n = 5, each). (d and e) IFN-γ production by CD8+ T cells (d) 656 
and the number of IFN-γ producing cells in CD4+ or CD8+ populations (e) in KBA (red) or 657 
control IgG (black) treated mice (n = 5, each). DNFB-sensitized mice were treated with KBA 658 
or control IgG 12 h after DNFB challenge and the skin samples were obtained 6 h later. *, P 659 
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< 0.05. 660 
 661 
Figure 4: Macrophages are essential for DC cluster formation. (a) Score of DC cluster 662 
number 24 h and 48 h after DNFB application in sensitization (red) or elicitation (green) 663 
phase of CHS (n=4, each). (b) Score of DC cluster number in non-treated (NT) mice and 664 
DNFB-applicated-C57BL/6 (WT), Rag2-deficient, aly/aly, MasTRECK, BasTRECK, 665 
LysM-DTR, and 1A8-treated mice (n=4, each). *, P < 0.05. (c) DC clusters observed in 666 
LysM-DTR BM chimeric mice with or without DT-treatment. Scale bar = 100 µm. (d) Ear 667 
swelling 24 h after DNFB application in LysM-DTR BM chimeric mice with (red) or without 668 
(black) DT-treatment (n = 5, each). (e) The number (left) and the % frequency (right) of 669 
IFN-γ producing CD8+ T cells in the ear 18 h after DNFB application in LysM-DTR BM 670 
chimeric mice with (red) or without (black) DT-treatment (n = 5, each). *, P < 0.05. 671 
 672 
Figure 5: Macrophages mediate perivascular DC cluster formation. (a) A distribution of 673 
dDCs (green) in the steady state (left) and in the elicitation phase of CHS (right). The white 674 
circles show DC clusters. Sebaceous glands visualized with BODIPY (green) are indicated by 675 
arrows. Blood vessels, yellow/red; macrophages, red. (b) A high magnification view of 676 
perivascular DC cluster. Scale bar = 100 µm.(c) Sequential images of dDCs (green) and 677 
macrophages (red) in the elicitation phase of CHS. The white dashed line represents the track 678 
of a DC. (d) Chemotaxis assay. % input of dDCs transmigrating into the lower chamber with 679 
or without macrophages prepared from the skin. 680 
 681 
Figure 6: IL-1α upregulates CXCR2 ligands expression in M2-phenotype macrophages to 682 
form DC clusters. (a) Scores of DC cluster numbers in NT or 24 h after hapten-painted sites 683 
in WT, IL-1R-, NALP3-, or caspase 1 (Casp1)-deficient mice (n=4, each). (b) Scores of DC 684 
cluster numbers in NT or 24 h after hapten-painted sites in isotype control IgG, 685 
anti-IL-α antibody, anti-IL-1β antibody, IL-1R antagonist, or pertussis toxin (Ptx)-treated 686 
mice (n=4, each). (c, d) Ear swelling 24 h after DNFB application (c) and the number (left) 687 
and the % frequency (right) of IFN-γ producing CD8+ T cells in the ear 18 h after DNFB 688 
application (d) in mice that lack both IL-1α and IL-1β (red) and WT (black) mice (n = 5, 689 
each) which were adoptively transferred with DNFB-sensitized T cells. *, P < 0.05. (e, f) 690 
Relative amount of Il1r1 and Cxcl2 mRNA expression. Quantitative RT-PCR analysis of 691 
mRNA obtained from M1 or M2-phenotype macrophages (e), cultured with (+) or without (-) 692 
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IL-1α (f) (n=4, each). (g) Scores of DC cluster numbers in NT or 24 h after hapten-painted 693 
sites in the presence (SB265610) or absence (vehicle) of a CXCR2 inhibitor (n=4, each). *, P 694 
< 0.05. (h, i) Ear swelling 24 h after DNFB application (h) and the number (right) and the % 695 
frequency (left) of IFN-γ producing CD8+ T cells 18 h after DNFB application (i) with (red) 696 
or without (black) SB265610-treatment (n = 5, each). *, P < 0.05. 697 
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